# Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients

> **NCT05821478** · PHASE3 · RECRUITING · sponsor: **Institut Pasteur** · enrollment: 92 (estimated)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy
- **DRUG:** Lymecyclin and corresponding placebos of the experimental arm

## Key facts

- **NCT ID:** NCT05821478
- **Lead sponsor:** Institut Pasteur
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-22
- **Primary completion:** 2027-02-28
- **Final completion:** 2028-02-27
- **Target enrollment:** 92 (ESTIMATED)
- **Last updated:** 2025-07-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05821478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05821478, "Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05821478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*